Keywords: elan, 1st-qtr, net, loss, widens, 6m, irish
Elan 1st-qtr net loss widens 20% to $102.6M
Article | 27 April 2009
Irish biotechnology firm Elan's first-quarter 2009 net loss widened 20% year-on-year to $102.6 million, on restructuring and US tax charges. The Dublin-based firm, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
